Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Last Updated: January 26, 2023

Details for Patent: 8,162,915

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,162,915 protect, and when does it expire?

Patent 8,162,915 protects NAROPIN and is included in one NDA.

This patent has twenty-five patent family members in nineteen countries.

Summary for Patent: 8,162,915
Title:Connector for packings containing medical liquids, and corresponding packing for medical liquids
Abstract: A connector for packings containing medical liquids, particularly infusion, transfusion or enteral bags, comprises a connecting part (1) for accommodating a spike for drawing out the liquid and comprises a closure part (3) that closes the passage (2) inside the connecting part (1). The connecting part (1) has an elastically deformable pinching off part (4) provided in the form of a tubular section with a non-circular cross-section. A base part (5), which widens on both sides is adjoined to said pinching off part (4) and can be integrated in the packing. During manufacturing, the packing is filled with liquid via the connecting part. After filling, the pinching off part is pressed together whereby preventing liquid from escaping. Afterwards, the closure part is placed onto the connecting part. The manufacturing of the packing is simplified by virtue of the fact that an additional tube for connecting the connector and packing is rendered unnecessary.
Inventor(s): Brandenburger; Torsten (Niddatal, DE), Heilmann; Klaus (St. Wendel, DE), Knierbein; Bernd (Neu-Anspach, DE)
Assignee: Fresenius Kabi Deutschland GmbH (Bad Homburg, DE)
Application Number:10/550,477
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,162,915
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 8,162,915

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Fresenius Kabi Usa NAROPIN ropivacaine hydrochloride SOLUTION;INJECTION 020533-006 Sep 24, 1996 AP RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Fresenius Kabi Usa NAROPIN ropivacaine hydrochloride SOLUTION;INJECTION 020533-007 Sep 24, 1996 AP RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,162,915

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany103 13 760Mar 27, 2003
PCT Information
PCT FiledJanuary 22, 2004PCT Application Number:PCT/EP2004/000487
PCT Publication Date:October 07, 2004PCT Publication Number: WO2004/084793

International Family Members for US Patent 8,162,915

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 407653 See Plans and Pricing
Australia 2004224795 See Plans and Pricing
Brazil PI0408780 See Plans and Pricing
Canada 2518617 See Plans and Pricing
China 100408013 See Plans and Pricing
China 1767799 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.